Roche receives request for additional information from the Federal Trade Commission
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has received a request for additional information, often referred to as a "second request," from the Federal Trade Commission ("FTC") in connection with Roche's proposed acquisition of Illumina, Inc. (NASDAQ: ILMN)
AstraZeneca files lawsuit against the FDA
- Details
- Category: AstraZeneca
AstraZeneca filed a lawsuit against the US Food and Drug Administration (FDA) in the US District Court for the District of Columbia to overturn the FDA's denial on 7 March 2012 of Citizen Petitions filed by AstraZeneca with regard to SEROQUEL® (quetiapine fumarate) tablets and SEROQUEL XR® (quetiapine fumarate) extended release tablets.
Pfizer's Prevnar 13® shown to be immunogenic in older children and adolescents
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced that data from a Phase 3 study of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.
Schwartz Center Receives $500,000 Grant from the Amgen Foundation
- Details
- Category: Amgen
The Schwartz Center for Compassionate Healthcare, a Boston-based nonprofit dedicated to strengthening the relationship between patients and their healthcare providers, today announced it has received a $500,000 grant from the Amgen Foundation.
Roche Annual General Meeting 2012
- Details
- Category: Roche
Roche's Annual General Meeting, held today in Basel, approved all of the Board of Directors' proposals. The 755 shareholders in attendance, representing 87.4% of a total of 160,000,000 bearer shares, approved Roche's 2011 Annual Report and Financial Statements.
GSK announces submissions for two influenza vaccines
- Details
- Category: GlaxoSmithKline
GSK has submitted US and EU regulatory applications seeking approval of a quadrivalent influenza vaccine for the "active immunisation of adults and children from 3 years of age for the prevention of influenza disease caused by influenza virus types A and B contained in the vaccine."
Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE:LLY) announced the launch of its global Innovation Starts Here initiative which supports Lilly's commitment to speeding the delivery of innovative new medicines to patients around the world.
More Pharma News ...
- GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan
- FDA approves first four-strain flu vaccine
- Bristol-Myers Squibb and Duke Translational Medicine Institute form strategic relationship
- Sanofi and Astellas to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc.
- Pfizer acquires Alacer Corp., a leading vitamin supplements company
- Sanofi and the Institut Pasteur create four prestigious awards
- Merck announces efficiency program across all businesses and regions